Cytarabine intravenous constant rate infusion (IV CRI) toxicity in cats with lymphoma has not been well documented. We aimed to assess toxicities following cytarabine IV CRI as a single-agent or within a multiagent protocol in cats with lymphoma. Medical records of cats with lymphoma treated with cytarabine IV CRI, with documented dose, route, duration and at least one follow-up visit between 1990 and 2024, were retrospectively reviewed. Adverse events (AEs) were retrospectively graded according to VCOG-CTCAE v2. Thirty-eight cats were included, and 70 doses were evaluated for AEs. Median cytarabine dose was 389.8 mg/m2 (range 100.1-697.3 mg/m2) over a median infusion duration of 6 h (range 2-17 h). A total of 103 AEs were documented across 70 administrations. Gastrointestinal AEs were the most common category: altered appetite (21/38 cats, 55.2%), vomiting (9/38, 23.7%; one grade 3, the rest grades 1-2), diarrhoea (2/38, 5.3%) and dysphagia (2/38, 5.3%). Anaemia was the most common hematologic AE (14/38 cats, 36.8%; five grade 1, two grade 2, five grade 3, two grade 4); six cats (15.8%) developed thrombocytopenia (four grade 1, two grade 2), and one cat (2.6%) developed grade 2 neutropenia. Lethargy was the most common constitutional AE (12/38 cats, 31.6%). IV CRI of cytarabine was generally tolerated, with predominantly low-grade AEs, although grade 3-4 anaemia was not uncommon. Response rate and clinical benefit remain unknown; investigation of alternative dosing regimens may help clarify its therapeutic potential.
更多
原文链接
分享
引用
